Farhan Bhatti, MD
Family Medicine · Lansing, MINPI 1326308057
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $204,463 of the $229,703 with a category attached, or 89.0%. AbbVie accounts for 96.9% of it on its own, with 41 other manufacturers making up the rest. Reporting peaked in 2020 at $44,555 and has fallen 64.6% since, to $15,778 in 2025. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 921 payments — averaging $249.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$222K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$749
- Otsuka America Pharmaceutical, Inc.$665
- Teva Pharmaceuticals USA, Inc.$616
- Alkermes, Inc.$480
- Neurocrine Biosciences, Inc.$409
- plus $4K from 36 others
What the payments were for
- Consulting fees$4,6132%
- Speaking & faculty fees$204,46389%
- Travel & lodging$9,7074%
- Food & beverage$10,4925%
- Education$4290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$215,128
- UBRELVY$1,313
- TRELEGY ELLIPTA$107
How this compares
$229,703 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 128 | $152,040 |
| VraylarCariprazine Hcl | 72 | $107,529 |
| OzempicSemaglutide | 81 | $92,587 |
| FarxigaDapagliflozin Propanediol | 89 | $91,780 |
| TrulicityDulaglutide | 71 | $73,200 |
| EliquisApixaban | 81 | $70,447 |
| MounjaroTirzepatide | 40 | $53,911 |
| JardianceEmpagliflozin | 35 | $43,950 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $25,822 |
| OxycontinOxycodone Hcl | 14 | $25,349 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $24,185 |
| LinzessLinaclotide | 20 | $19,870 |
| CaplytaLumateperone Tosylate | 12 | $18,813 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $17,678 |
| MyrbetriqMirabegron | 19 | $16,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $369 | $176,225162 claims |
| AbbVieVraylar, Linzess | $222,483 | $127,39992 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $240 | $127,110111 claims |
| Novo NordiskOzempic | $282 | $92,58781 claims |
| AstraZenecaFarxiga | $58 | $91,78089 claims |
| PfizerEliquis | $372 | $70,44781 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $286 | $54,53747 claims |
| Alkermes, Inc.Lybalvi | $480 | $25,82217 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $749 | $18,81312 claims |
| MerckJanuvia | $83 | $7,23711 claims |
| Sanofi-aventis U.S. LLCLantus | $100 | $4,50022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Lansing
- Laurie RozekLansing$86K
- Amy TrinhLansing$19K
- Rosemary RoperLansing$17K
- Mark SchaarLansing$16K
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Jeffrey DeitchSterling Heights$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.